- Home
- SCLXW vs NYMTL Comparison
SCLXW vs NYMTL Comparison
Compare SCLXW & NYMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- NYMTL
- Stock Information
- Founded
- SCLXW N/A
- NYMTL N/A
- Country
- SCLXW United States
- NYMTL United States
- Employees
- SCLXW 111
- NYMTL 70
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- NYMTL Real Estate Investment Trusts
- Sector
- SCLXW Health Care
- NYMTL Real Estate
- Exchange
- SCLXW Nasdaq
- NYMTL Nasdaq
- Market Cap
- SCLXW N/A
- NYMTL N/A
- IPO Year
- SCLXW N/A
- NYMTL N/A
- Fundamental
- Price
- SCLXW $0.46
- NYMTL $21.97
- Analyst Decision
- SCLXW
- NYMTL
- Analyst Count
- SCLXW 0
- NYMTL 0
- Target Price
- SCLXW N/A
- NYMTL N/A
- AVG Volume (30 Days)
- SCLXW 4.0K
- NYMTL N/A
- Earning Date
- SCLXW 03-07-2025
- NYMTL N/A
- Dividend Yield
- SCLXW N/A
- NYMTL N/A
- EPS Growth
- SCLXW N/A
- NYMTL N/A
- EPS
- SCLXW N/A
- NYMTL N/A
- Revenue
- SCLXW $55,152,000.00
- NYMTL N/A
- Revenue This Year
- SCLXW N/A
- NYMTL N/A
- Revenue Next Year
- SCLXW N/A
- NYMTL N/A
- P/E Ratio
- SCLXW N/A
- NYMTL N/A
- Revenue Growth
- SCLXW 22.02
- NYMTL N/A
- 52 Week Low
- SCLXW $0.18
- NYMTL N/A
- 52 Week High
- SCLXW $0.18
- NYMTL N/A
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- NYMTL 52.20
- Support Level
- SCLXW N/A
- NYMTL $21.97
- Resistance Level
- SCLXW N/A
- NYMTL $22.20
- Average True Range (ATR)
- SCLXW 0.00
- NYMTL 0.12
- MACD
- SCLXW 0.00
- NYMTL 0.01
- Stochastic Oscillator
- SCLXW 0.00
- NYMTL 46.51
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About NYMTL New York Mortgage Trust Inc. 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock $0.01 par value per share
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets. Geographically operates in USA states California, New York, Florida, New Jersey, Illinois, maximum from California.